Figure 5.

CD8⁺ T cells induced by recombinant PPV:VLP-(LCMV) fully protect mice against a lethal LCMV challenge. BALB/c mice were injected i.p. on days 0 and 21 with 10 μg of PPV:VLP, 10 μg of PPV:VLP-(LCMV), PBS, or 10⁵ pfu of LCMV. Two groups were also treated on days −1, 0, +1, 7, 14, and 20 with anti-CD4 or anti-CD8 mAbs. After 7 (A) or 49 (B) days, mice were challenged i.c. with 10^1.7 pfu of LCMV. Survival was recorded for 21-days period. The percent survival and the number of surviving mice/the number of total mice (∗) are the cumulative results of four experiments. ND, not determined.